Aurelie Najm AurelieRheumo
3 years 11 months ago
A new murine model to study Pso and PsA!
Immunodeficient mice NSG-SGM3 🐁 injected w/ serum & PBMCs from Pso and/or PsA pts = pro & arthritis (same phenotype than pts)
Mice skin & synovia >effector memory CD8 T cell & < naïve
https://t.co/cxSvEZC9Ly
Abs#L04 #ACR22 @Rheumnow https://t.co/hfbtSsP3f8
TheDaoIndex KDAO2011
3 years 11 months ago
#ACR22 #GIOP Guidelines Case:
In pt < 40 yo who had renal transplant on 7.5 mg/day or higher with low Z score, consult mineral/metabolism expert but you can consider Rx. @rheumnow https://t.co/RJuRi7EPX1
sheila RHEUMarampa
3 years 11 months ago
Are we giving enough HCQ?🤔
Findings from the study of Dr J Nestor show that ⬇️dose HCQ (</= 5mkd or <400mg/day) is associated w/ ⬆️hospitalizations for #lupus (adj. OR 4.41; 3.48)
#ACR22 @RheumNow ABST#1654 @rheumarhyme #ACRBest https://t.co/XCoZgbdOim
TheDaoIndex KDAO2011
3 years 11 months ago
Is he the only one?
Dr. Stone shared that he kept his notes from internship and residency! I kept an old tshirt from college, but this is a new level. #ACR22 @rheumnow https://t.co/Wj9c2Uizxt
A new target for treatment in AxSpA is the dual inhibition of IL17A and IL17F (IL17A/F). IL17A is a key driver of the inflammation in the AxSpA and Psoriatic Arthritis (PsA). IL17A and its structurally related IL17F share biologic functional properties. Inhibition of both cytokines (IL17A/F) should result in a greater clinical benefit in AxSpA and PsA than IL17A inhibition alone.
Dr. John Cush RheumNow
3 years 11 months ago
RheumNow’s expanded coverage of the #ACR22 Annual meeting is sponsored in part by Bristol-Myers Squibb. All content chosen by RheumNow & its Faculty.
Richard Conway RichardPAConway
3 years 11 months ago
Ozen et al. Safety Opioids vs NSAIDs in RA. Similar risks except 2-fold increase in VTE with opioids. @RheumNow #ACR22 Abstr#1646 https://t.co/kWBf8t4TFh https://t.co/dxKoilOhFX
Aurelie Najm AurelieRheumo
3 years 11 months ago
FORWARD databank RA
4500+ opioid & 11000+ NSAID
MACE 133 vs. 392 (18.2/1000 PY vs. 14.6/1000 PY)
Deaths 95 vs. 228 (12.6/1000 PY vs. 8.2/1000 PY)
IR MACE & mortality NSAID < Opioids
Driven by VTE > Opioids vs NSAIDs HR=2.45
https://t.co/fl7cJNGrvu
Abs#1646 #ACR22 @Rheumnow https://t.co/wV5hYMfYLl
Richard Conway RichardPAConway
3 years 11 months ago
Brooks et al. Risk lung cancer higher in RA (aHR 1.53) and RA-ILD (aHR 3.06) than controls. Persisted in non-smokers, non-RA-ILD, incident RA @RheumNow #ACR22 Abstr#1647 #ACRbest https://t.co/c18k9OLDIm https://t.co/UTgYZAmfmk
TheDaoIndex KDAO2011
3 years 11 months ago
Dr. B Humphrey #ACR22 #Osteoporosis Guidelines:
Treatment algorithms for GIO and in special populations (age < 18) @rheumnow https://t.co/dZ02kuOUeH
Richard Conway RichardPAConway
3 years 11 months ago
Juge @Juge_P_A @PhilippeDieude et al. Increased mortality in RA-ILD. HR 3.4 vs RA. <75 HR 4.8 . ILD first HR 8.4 @RheumNow #ACR22 Abstr#1959 #ACRbest https://t.co/mnbeBPuyC7 https://t.co/sLU2ZuTMw7
David Liew drdavidliew
3 years 11 months ago
Of course, imaging itself can be useful in PMR in many situations - and, like GCA, there are merits to all of ultrasound, MRI, and PET/CT.
Nice summary slide @drceowen #ACR22 @RheumNow https://t.co/1LO3DvW7tm
Eric Dein ericdeinmd
3 years 11 months ago
14M111 Updated ACR Guidelines for Glucocorticoid-Induced Osteoporosis #ACR22 🦴🦴
Special pops recs for:
Organ transplant - against romosozumab (CVD risk)
Women of child bearing age (not planning) - BIS/TERI
Children - Vit D/Ca unless Fx
Very high doses: more aggressive
@RheumNow https://t.co/xY7Yc3BANj
Julian Segan JulianSegan
3 years 11 months ago
Paul Emery presenting phase 2 data Peresolimab in RA. Novel mechanism aiming to restore immune homeostasis. Exciting for rheumatic disease beyond RA.
@RheumNow #ACR22 #LateBreaking https://t.co/oOjvo5YmDB
Richard Conway RichardPAConway
3 years 11 months ago
Tam et al . Increased CV risk in early RA abrogated with treat to target approach. @RheumNow #ACR22 Abstr#1649 https://t.co/i2iHyPoKf0 https://t.co/u0R00oolyP
